Skip to main content
. 2018 Jul 17;20(8):857–870. doi: 10.1016/j.neo.2018.06.008

Figure 6.

Figure 6

ETV7 and DNAJC15 levels inversely correlate with clinical status of breast cancer patients and ETV7 targeting could be exploited pharmacologically. A) ETV7, DNAJC15 and ABCB1 expression levels from microarray data (GSE76540) of MCF7 cells resistant to Adriamycin -MCF7/ADR- (e.g. Doxorubicin). Presented are the averages and standard deviations of at least three biological replicates. B) ETV7 and DNAJC15 expression levels from microarray data of Triple Negative Breast Cancer patients treated with neoadjuvant chemotherapy who were showing recurrence or not for the disease (GSE43502). C) ETV7 expression levels measured by RT-qPCR from MDA-MB-231 cells untreated (Mock) or treated with Quercetin 50μM or Genistein 30μM for 16 hours. Bars represent averages and standard deviations of at least three biological replicates. D) MTT assay in MDA-MB-231 cells over-expressing ETV7 or its empty vector and treated with increasing concentration of Quercetin. Experiments are done in quadruplicate. * = P-value <0.01.